BIOSPECIFICS TECH (NASDAQ:BSTC)
30.78
0.44 (1.41%)
| BIOSPECIFICS TECH (NASDAQ:BSTC) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $31.22 | 52 Week High | $33.00 | ||
| Open | $31.42 | 52 Week Low | $10.50 | ||
| Day High | $32.00 | P/E | 54.00 | ||
| Day Low | $30.36 | EPS | $0.57 | ||
| Volume | 22,487 | ||||
| More BSTC Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| SPR | 2 | TEVA | 1 |
| ATPG | 1 | CLR | 1 |
| EOG | 1 | GTSI | 1 |
| IPCC | 1 | LTRX | 1 |
| NFG | 1 | PLUG | 1 |
| SBUX | 1 | TCHC | 1 |
Entities who have mentioned BSTC
- Goldman Sachs Conviction Buy List | View Related Stories »
- Citi | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Carl Icahn | View Related Stories »
- Initial Jobless Claims | View Related Stories »
- GLG Partners | View Related Stories »
- Trading Radar | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
View All ReportsStreetInsider.com Reports on BSTC
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Morning Movers 9/17: HYTM, IVAN, XNPT, RNN, BSTC, AMR, SOLF Higher; DARA, SNV, HW Lower
- FDA Unanimously Recommends Approval of BioSpecifics' (BSTC) XIAFLEX(TM)
- BioSpecifics Technologies (BSTC) Stock Halted Ahead of FDA Meeting On XIAFLEX
- BioSpecifics Technologies (BSTC) Added to Russell 3000 and Russell 2000 Indexes
View All Press ReleasesCompany Press Releases on BSTC
- Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
- BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
- IPOdesktop.com Internet Radio Series Interviews Orthopedic Surgeon Dr. Eugene Wolf, Who Sees Multiple Applications in His Specialty for BioSpecifics' XIAFLEX(TM)
- BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
- IPOdesktop.com Internet Radio Series Interviews Stanford's Dr. Rod Hentz, Veteran Plastic Surgeon and Physician Consultant to BioSpecifics
StreetInsider Reports on BSTC by Category
View All FilingsSEC Filings on BSTC
- Form 8-K BIOSPECIFICS TECHNOLOGIE For: Nov 06
- Form 10-Q BIOSPECIFICS TECHNOLOGIE For: Sep 30
- Form 8-K BIOSPECIFICS TECHNOLOGIE For: Nov 05
- Form 4 Wegman Thomas For: Oct 28
- Form 8-K BIOSPECIFICS TECHNOLOGIE For: Sep 29
Comments on recent BSTC articles
Comments on BSTC
No comments are currently available.
on Jun 23, 2009
at 07:24 PM xiaflex THE OFF LABEL INDICATIONS FOR A COLLAGENASE BASED INJECTIBLE FOR BURN SCARS, POST SURGICAL SCARS, KELOIDS, AS WELL AS OTHER INDICATIONS WOULD GREATLY EXPAND THE USE OF XIAFLEX.
Article: Hapoalim Securities Initiates Coverage on BioSpecifics (BSTC) with a Market Outperform; Possible Acquisition Play